How GPCR-targeting therapies are advancing the fight against inflammatory disease
Drug Target Review
JUNE 16, 2025
However, due to its unique biology and structural complexity, PAR2 has proven notoriously difficult for the pharmaceutical industry to effectively target. Prior to joining Domain, Stephan established and led the Medicinal Chemistry Department at Faust Pharmaceuticals and was a senior scientist at Evotec.
59 
Let's personalize your content